

Active specific immunotherapy (ASI) and Gcmaf Forte in management of metastatic invasive carcinoma – overview of the therapeutic modalities and a case report

Roni Lara Moya

University of Mogi das Cruzes – Sao Paulo, Brazil

Abstract

Metastatic most cancers is often a lethal illness with low survival charge that in a course of its development implies a pathogenic cascade concerning inflammation, overexpression of reactive oxygen species, loss of DNA repair, Understanding the flow into-interplay mechanism some of the immune costimulatory and inhibitory molecules on one aspect and tumors cells is a key point in the development of a a hit immunotherapeutic method to fight competitive cancers. The active particular immunotherapy (ASI) and the GC protein macrophage activating component (GcMAF) are immunotherapies capable of modulating the innate and adaptive immunity in opposition to maximum cancers. The aim of this talk is to offer a case of an invasive metastatic carcinoma dealt with with ASI and GcMAF Forte and discusses the potentials of the individualized immunotherapy in superior paperwork of maximum cancers. Immunotherapy improves reputation of immune tool and as a quit result it's going to boom patient's lifestyles span (and probable survival fee). In stop, the ASI and GcMAF Forte may additionally provide a promising ability immunological biomedical approach to boost immunity and beautify existence expectancy in patients with metastatic most cancers.

ronimoya@gmail.com

Note: This work is partly presented at 9th INTERNATIONAL CONFERENCE AND EXHIBITION ON Advanced Cell and Gene Therapy, March 21-22, 2019 | Rome, Italy